Viking Therapeutics, Inc. (VKTX) income statement
NASDAQ · Healthcare · Biotechnology · 53 employees · CEO Brian Lian
- Price
- $27.28 +1.56%
- Market cap
- $3.48B
- Enterprise value
- $3.06B
- Last report
- Q3 '26 filed 2026-10-29
- Next report
- 2027-02-10 EPS est. -$1.38
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $114K | $94K | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$114K | -$94K | $0 | $0 | $0 | |
| Research & development | $20.5M | $24.1M | $23.8M | $22.8M | $31M | $41.4M | $60.2M | $90M | $153M | $150M | $116M | $167M | |
| General & administrative | $8.78M | $9.97M | $10.3M | $13.8M | $15.3M | $14.1M | $14.4M | $8.61M | $11.3M | $14M | $16.8M | $20.3M | |
| Operating expenses | $29.3M | $34.1M | $34.1M | $36.6M | $46.2M | $55.5M | $74.6M | $98.6M | $165M | $164M | $133M | $187M | |
| Operating income | -$29.3M | -$34.1M | -$34.1M | -$36.6M | -$46.2M | -$55.5M | -$74.6M | -$98.6M | -$165M | -$164M | -$133M | -$187M | |
| Interest income | $4.71M | $6.75M | $11.8M | $11.5M | $10.8M | $9.86M | $9.03M | $7.77M | $7.04M | $5.8M | $4.55M | $4.01M | |
| Interest expense | $26K | $28K | $18K | $24K | $24K | $24K | $24K | $8K | $0 | $0 | $0 | $88K | |
| Other non-operating income (gains on investments, FX ...) | -$4.71M | -$6.75M | -$11.8M | -$11.6M | -$10.8M | -$9.86M | -$9.04M | -$7.78M | -$7.08M | -$5.8M | -$4.58M | -$4.01M | |
| Total non-operating income | $4.68M | $6.72M | $11.8M | $11.6M | $10.8M | $9.84M | $9.01M | $7.77M | $7.08M | $5.8M | $4.58M | $3.93M | |
| Income before tax | -$24.6M | -$27.4M | -$22.3M | -$24.9M | -$35.4M | -$45.6M | -$65.6M | -$90.8M | -$158M | -$158M | -$128M | -$183M | |
| Net income | -$24.6M | -$27.4M | -$22.3M | -$24.9M | -$35.4M | -$45.6M | -$65.6M | -$90.8M | -$158M | -$158M | -$128M | -$183M | |
| EPS (basic) | -$0.25 | -$0.26 | -$0.20 | -$0.22 | -$0.32 | -$0.41 | -$0.58 | -$0.81 | -$1.38 | -$1.37 | -$1.10 | -$1.55 | |
| EPS (diluted) | -$0.25 | -$0.26 | -$0.20 | -$0.22 | -$0.32 | -$0.41 | -$0.58 | -$0.81 | -$1.38 | -$1.37 | -$1.10 | -$1.55 | |
| Shares (basic, weighted) | 100M | 103M | 110M | 111M | 111M | 112M | 112M | 112M | 114M | 116M | 116M | 118M | |
| Shares (diluted, weighted) | 100M | 103M | 110M | 111M | 111M | 112M | 112M | 112M | 114M | 116M | 116M | 118M | |
| Depreciation & amortization | $74K | $74K | $75K | $87K | $110K | $111K | $112K | $114K | $94K | $85K | $157K | $0 | |
| EBITDA | -$24.5M | -$27.3M | -$22.2M | -$24.8M | -$35.3M | -$45.5M | -$65.4M | -$90.7M | -$158M | -$158M | -$128M | -$183M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $260K | $0 | $0 | $0 | $0 | $0 | $431K | |
| Gross profit | $0 | $0 | $0 | -$260K | $0 | $0 | $0 | $0 | $0 | -$431K | |
| Research & development | $9M | $13.7M | $19M | $23.6M | $31.9M | $45M | $54.2M | $63.8M | $102M | $345M | |
| General & administrative | $4.85M | $5.33M | $7.12M | $0 | $10.7M | $10.7M | $16.1M | $37M | $49.3M | $48.4M | |
| Operating expenses | $13.8M | $19.1M | $26.2M | $32.4M | $42.7M | $55.7M | $70.4M | $101M | $151M | $393M | |
| Operating income | -$13.8M | -$19.1M | -$26.2M | -$32.7M | -$42.7M | -$55.7M | -$70.4M | -$101M | -$151M | -$393M | |
| Interest income | $83.6K | $98.1K | $3.27M | $7.05M | $3.23M | $703K | $1.59M | $15M | $40.9M | $33.7M | |
| Interest expense | $2.03M | $1.95M | $562K | $146K | $106K | $18K | $59K | $88K | $94K | $0 | |
| Other non-operating income (gains on investments, FX ...) | -$1.15M | -$443K | -$4.66M | -$7.05M | -$3.27M | -$710K | -$1.55M | -$15M | -$41.1M | -$33.8M | |
| Total non-operating income | -$885K | -$1.51M | $4.1M | $6.91M | $3.17M | $692K | $1.49M | $14.9M | $41M | $33.7M | |
| Income before tax | -$14.7M | -$20.6M | -$22.1M | -$25.8M | -$39.5M | -$55M | -$68.9M | -$85.9M | -$110M | -$360M | |
| Net income | -$14.7M | -$20.6M | -$22.1M | -$25.8M | -$39.5M | -$55M | -$68.9M | -$85.9M | -$110M | -$360M | |
| EPS (basic) | -$0.90 | -$0.79 | -$0.38 | -$0.36 | -$0.50 | -$0.70 | -$0.88 | -$0.91 | -$1.01 | -$3.19 | |
| EPS (diluted) | -$0.90 | -$0.79 | -$0.38 | -$0.36 | -$0.50 | -$0.70 | -$0.88 | -$0.91 | -$1.01 | -$3.19 | |
| Shares (basic, weighted) | 16.3M | 26M | 57.6M | 72M | 72.6M | 77.2M | 76.8M | 94.3M | 109M | 113M | |
| Shares (diluted, weighted) | 16.3M | 26M | 57.6M | 72M | 72.6M | 77.2M | 76.8M | 94.3M | 109M | 113M | |
| Depreciation & amortization | $1.93M | $19.1M | $26.2M | $260K | $277K | $296K | $291K | $292K | $346K | $431K | |
| EBITDA | -$10.8M | $443K | $4.66M | -$25.4M | -$39.1M | -$54.7M | -$68.5M | -$85.5M | -$110M | -$359M |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-02